Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells

Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells

Increasing evidence supports an association between Alzheimer's disease (AD) and diabetes. Rosiglitazone, a peroxisome proliferator-activated receptor-γ (PPARγ) agonist, which is an anti-diabetic agent against type 2 diabetes, is currently in Phase III clinical trials in AD patients because ros...

Full description

Bibliographic Details
Main Authors: Seung-Yong Yoon, Jeong-Su Park, Jung-Eun Choi, Jin-Myung Choi, Woo-Je Lee, Seong-Who Kim, Dong-Hou Kim
Format: Article
Language:English
Published: Elsevier 2010-11-01
Series:Neurobiology of Disease
Subjects:
Alzheimer's disease
Diabetes
Tau phosphorylation
Rosiglitazone
PPARγ
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996110002299

Internet

http://www.sciencedirect.com/science/article/pii/S0969996110002299

Similar Items